Staphylococcus aureus strains with resistance to methicillin or oxacillin (MRSA) represent one of the main nosocomial pathogens at present. MRSA infections are clearly associated with higher mortality and economic cost than those caused by methicillin-susceptible S. aureus (1). In Spain, the prevalence of methicillin resistance among S. aureus isolates has increased since the 1990s and in some cases has now reached levels higher than 30% (2).
respectively. However, the values for all parameters increased to 100% when the three strains were analyzed after induction of the mecA gene product with cefoxitin.
The main advantage of the AST-P559 card is the incorporation of two tests to provide simultaneous determination of oxacillin MICs as well as cefoxitin screening. Several studies (6, 7) have shown that cefoxitin is a better predictor of the presence of mecA than oxacillin, and, indeed, Velasco et al. (7) reported an increase of 2% in sensitivity to detect mecA when the cefoxitin screening test was used in addition to the oxacillin MIC. For these reasons, the simultaneous presence of two tests (oxacillin MIC and cefoxitin screening) in the same card may offer a noticeable advantage for detection of some mecA-negative S. aureus isolates which are identified by cefoxitin screening rather than oxacillin MIC. In addition, information about susceptibility to antibiotics against gram-positive microorganisms is provided by this card, which offers an undoubted advantage with respect to chromogenic agars, agglutination latex, or molecular techniques, since they only detect the marker of resistance to oxacillin. In addition to that, the possibility of diagnosis of an MRSA infection in 4 h (by the software interpretation of the cefoxitin screening) will make the use of this automated method very attractive for clinical microbiology laboratories worldwide. a Became positive after preincubation with agar containing 6 g/ml of cefoxitin.
